Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections
NCT ID: NCT02171338
Last Updated: 2014-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
55 participants
INTERVENTIONAL
2013-10-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Procalcitonin as a Marker of Bacterial Pneumonia
NCT00415753
Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD)
NCT01950936
Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)
NCT00132860
Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
NCT00688610
The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice
NCT04216277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Lower respiratory tract infections such as pneumonia and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are frequent reasons for patient contact in both the primary and secondary sectors. Identifying which patients that could benefit from treatment with antibiotics is a great challenge to the health sector. This is why patients often are treated with antibiotics if there is a mere suspicion of the above-mentioned disorders, even if they are not proved for certain.
An increasing amount of data suggests that procalcitonin (PCT) could serve as a possible marker of respiratory tract infections caused by bacteria. Alongside the conventional clinical parameters, the level of PCT is regarded as a promising means to decide whether to treat with antibiotics and how long such a treatment should endure. When an infection is under control by the immune system of the individual or by treatment with antibiotics, the level of PCT will diminish by 50% on a daily basis. Accordingly, a decline in the PCT levels should indicate a favorable response to antibiotic treatment. Therefore there is a need to further investigate if the PCT levels can be used, in the everyday clinic, to diagnose patients with pneumonia or AECOPD caused by bacteria and if this could have an effect on the use of antibiotics, thus optimizing the treatment of the patients.
The purpose of this research project is to compare the amount of antibiotics consumed using standard treatment and treatment based on the PCT levels of patients with lower respiratory tract infections, respectively.
With the research at hand, a clarification of whether a measurement of PCT can serve as a diagnostic tool to distinguish between bacterial and non-bacterial infections in patients that are suspected of having pneumonia or AECOPD is desirable. In extension, this study wants to clarify if the PCT levels can indicate when a potential antibiotic treatment should be initiated and if the use of a PCT-based treatment in the daily clinical work could lower the consumption of antibiotics.
The hypothesis is that PCT will be increased (≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively) in lower respiratory tract infections caused by bacteria, whereas PCT should only be slightly increased in non-bacterial lower respiratory tract infections if at all. It is expected that using a PCT-based treatment in lower respiratory tract infections could lower the consumption of antibiotics, while at the same time it should not prove a greater health risk to patients than by using a standard treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibiotic treatment based on PCT-level
Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).
With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started.
PCT-level
PCT-level is available to the treating doctor.
Antibiotic treatment based on PCT-level
PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.
The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above.
Control
Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.
PCT-level will be measured but the treating doctor has no access to the result.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCT-level
PCT-level is available to the treating doctor.
Antibiotic treatment based on PCT-level
PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.
The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical and paraclinical signs of pneumonia and/or AECOPD.
Exclusion Criteria
* Terminal patients.
* Patients with known abscess in the lungs and/or emphysema.
* Patients who have received treatment with strong doses (\>5mg/day) of biotin (vitamin B7 og B8) within the last eight hours.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Sjælland
OTHER
Aase and Ejnar Danielsens Foundation
OTHER
Holbaek Sygehus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans Ibsen, M.D., D.M.Sc
Role: STUDY_DIRECTOR
Holbaek Sygehus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holbæk Hospital
Holbæk, Holbæk, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJ-RO-01, j.nr. 12-000179
Identifier Type: REGISTRY
Identifier Source: secondary_id
SJ-342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.